Skip to main content
NOVOGENE CO., LTD. logo

NOVOGENE CO., LTD. — Investor Relations & Filings

Ticker · 688315 ISIN · CNE1000052X3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 558 across all filing types
Latest filing 2022-04-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688315

About NOVOGENE CO., LTD.

https://www.novogene.com

Novogene Co., Ltd. is a global provider of genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics analysis. The company offers a comprehensive suite of services, including whole genome sequencing, transcriptomics, epigenomics, and metagenomics, alongside specialized solutions for single-cell analysis and clinical diagnostics. Utilizing advanced high-throughput sequencing platforms and proprietary bioinformatics pipelines, Novogene supports research across diverse fields such as human health, agriculture, and environmental science. The organization serves a broad client base encompassing academic institutions, pharmaceutical companies, and biotechnology firms. With a focus on data quality and technical expertise, Novogene facilitates large-scale genomic studies and precision medicine initiatives through its network of high-capacity laboratories and integrated data management systems.

Recent filings

Filing Released Lang Actions
北京诺禾致源科技股份有限公司2021年年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021年度募集资金存放与实际使用情况的专项报告" which translates to "2021 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised through an IPO, the usage of these funds, management and regulatory compliance related to the raised funds, and includes audit opinions from an accounting firm and a sponsor institution. The document is focused on the management and use of capital raised by the company, including detailed tables of fund usage and regulatory compliance statements. This type of document is a specialized report on capital raising and fund usage, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual report (10-K), nor an audit report (AR) in the standalone sense, nor a regulatory filing (RNS) or announcement of a report (RPA). The document length is sufficient and contains substantive financial and regulatory information about capital usage. Therefore, the best classification is CAP.
2022-04-12 Chinese
北京诺禾致源科技股份有限公司2021年年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the year 2021 by Beijing Novogene Technology Co., Ltd. It details the cash dividend per share, total dividend amount, reasons for the dividend payout ratio being below 30%, and the decision-making process including board and supervisory opinions. It does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related explanations. The document is relatively short (2984 characters) and serves as an official announcement of the dividend distribution plan rather than a full annual report or earnings release. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2022-04-12 Chinese
北京诺禾致源科技股份有限公司2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The document is extensive (247 pages) and includes audited financial statements with signatures from the accounting firm and company officers. It also includes detailed financial metrics, quarterly data, and comprehensive management commentary. These characteristics align with the definition of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification document, and the length and content confirm it is the full report itself. FY 2021
2022-04-12 Chinese
北京诺禾致源科技股份有限公司独立董事关于第二届董事会第二十五次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on two agenda items for the company's board meeting: the appointment of the 2022 audit firm and the expected 2022 related party transactions. It references compliance with company law, listing rules, and company articles. The document does not contain financial statements or audit results but is an opinion or approval related to governance and audit matters. It is not an audit report itself, nor an annual or interim report. It is related to board/management information as it concerns board meeting agenda and approvals by independent directors. The document length is short (897 characters), and it is not an announcement of a report publication but a governance-related opinion document. Therefore, the best classification is Board/Management Information (MANG).
2022-04-12 Chinese
北京诺禾致源科技股份有限公司第二届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Beijing Nuohe Zhiyuan Technology Co., Ltd. It includes approvals of various reports and proposals related to the 2021 fiscal year, such as the annual board work report, general manager's report, independent directors' report, audit committee report, financial statements, profit distribution plan, and internal control evaluation report. It also discusses proposals for 2022 activities and authorizations. The document repeatedly states that these matters will be submitted to the shareholders' meeting for approval. The document is not the actual annual report or financial statements but a board meeting resolution announcement regarding these reports and proposals. It is a formal board/management information disclosure about board decisions and management reports, not the reports themselves or their publication announcements. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5073 characters) and content support this classification with high confidence.
2022-04-12 Chinese
中信证券股份有限公司关于北京诺禾致源科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of temporarily idle raised funds by Beijing Novogene Technology Co., Ltd. for cash management. It references regulatory approvals, fundraising amounts, investment projects, and compliance with securities regulations. The document is not a full financial report but a formal verification and opinion on the use of raised funds, including risk control and internal decision procedures. It is a regulatory compliance and verification document related to fundraising and cash management, not an annual or interim report, earnings release, or other financial statement. The document length is 3329 characters, which is relatively short but contains substantive content rather than just an announcement. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories like Annual Report or Capital/Financing Update.
2022-04-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.